INS and metabolic dysfunction-associated steatohepatitis: Adiponectin levels were associated with a reduced risk of moderate/severe steatosis (OR 0.83, 95% c.i. 0.72-0.96), NASH (OR 0.86, 95% c.i. 0.75-0.98), and of fibrosis (OR 0.84, 95% c.i. 0.74-0.95) independently of age, sex, BMI, ALT, insulin, glucose levels, and FFAs.